WASHINGTON (AP) — A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure.
Search Results - stltoday.com, St. Louis Post-Dispatch: Business
Tue, 12/01/2015 - 8:47am
WASHINGTON (AP) — A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure.